Updates and advances in multiple sclerosis neurotherapeutics Supplementary table

The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-modifying

therapies (DMTs) with improved efficacy and safety, in addition to an expanding pipeline of agents with

novel mechanisms, provide more options for patients withMS. While treatment of MS neuroinflammation

is well tailored in the existing DMT armamentarium, concerted efforts are currently underway for

identifying neuropathological targets and drug discovery for progressive MS. There is also ongoing

research to develop agents for remyelination and neuroprotection. Further insights are needed to guide

DMT initiation and sequencing as well as to determine the role of autologous stem cell transplantation

in relapsing and progressive MS. This review provides a summary of these updates.